Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Total Peptides: 32
Back to Home

Tesamorelin

Growth Hormone-Releasing Hormone (1-44) amide

Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.

Daily Implementation Guide

Daily Implementation Schedule

Lifestyle Integration Strategies

Nutrition Optimization

  • •High-protein meals (30-40g per meal)
  • •Eat slowly to enhance satiety effects
  • •Stay hydrated (3+ liters daily)
  • •Avoid high-fat meals on injection day

Exercise Enhancement

  • •Start with 150 min moderate exercise weekly
  • •Resistance training 2-3x per week
  • •Monitor energy levels during escalation
  • •Adjust intensity based on side effects

Sleep & Recovery

  • •Maintain consistent sleep schedule
  • •Monitor for sleep quality improvements
  • •Track energy levels throughout day
  • •Adjust injection timing if affecting sleep

Progress Tracking

Weekly Weight
Track: Every Monday AM
Target: 1-2 lbs/week loss
Waist Circumference
Track: Monthly
Target: 2-4 inches reduction
Energy Levels
Track: Daily (1-10 scale)
Target: Gradual improvement
Side Effects
Track: Daily
Target: Decrease over time
HbA1c (if diabetic)
Track: Every 3 months
Target: <7% or per doctor

SUCCESS MILESTONES

5% weight loss8-12 weeks
10% weight loss16-24 weeks
15% weight loss32-48 weeks
20%+ weight loss52-72 weeks

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Tesamorelin (Egrifta) is an FDA-approved prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment requires proper patient selection, monitoring, and management of potential side effects. Patients must be evaluated for contraindications including active malignancy and diabetic complications. Regular monitoring of glucose levels, IGF-1, and treatment response is essential for safe and effective use.